Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer

Background: The use of biomarkers has become increasingly important in the diagnosis and treatment of several malignancies, including breast cancer. Among the established biomarkers, receptor tyrosine-protein kinase erbB-2 (HER-2/ neu) has been found to be of a predictive and prognostic role in brea...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maral Mokhtari, Mohammad Hadi Khosravi
Formato:	article
Lenguaje:	EN
Publicado:	Shiraz University of Medical Sciences 2021
Materias:	breast neoplasms her 2 proto-oncogene protein in situ hybridization Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2506265dea124190a6c339331ad14c1b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2506265dea124190a6c339331ad14c1b
record_format	dspace
spelling	oai:doaj.org-article:2506265dea124190a6c339331ad14c1b2021-11-29T10:40:47ZUtility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer2008-67092008-668710.30476/mejc.2021.84845.1234https://doaj.org/article/2506265dea124190a6c339331ad14c1b2021-10-01T00:00:00Zhttps://mejc.sums.ac.ir/article_47490_6cde1a2dab1919f8653d0d21973a787c.pdfhttps://doaj.org/toc/2008-6709https://doaj.org/toc/2008-6687Background: The use of biomarkers has become increasingly important in the diagnosis and treatment of several malignancies, including breast cancer. Among the established biomarkers, receptor tyrosine-protein kinase erbB-2 (HER-2/ neu) has been found to be of a predictive and prognostic role in breast cancer patients. Method: 94 patients with primary breast cancer were enrolled in our prospective study between 2016 and 2017. 5 cc clot blood samples were taken for serum HER- 2/neu testing at the time of diagnosis of breast cancer. The patients’ demographic data, tumor characteristics, including tumor size, tumor grade, presence of lymph node involvement, and stage, hormone receptor, and tissue HER-2/neu status of the subjects were recorded following tumor removal. Results: All of the patients were female with the age range of 27 to 80 years (the mean of age was 49.66. 36 patients (38.3%) had positive tissue HER-2 results and 58 (61.7%) had negative results. In those with high level serum HER-2 ECD, 28(77.7%) had positive tissue HER-2 and 8(22.2%) had negative results. Moreover, in the patients with low level serum HER-2 ECD, 8(13.7%) had positive tissue HER-2 and 50(86.2%) had negative results with the sensitivity of 77.7% and specificity of 86.2%. HER2 ECD levels were highly concordant with tissue HER2 status, with a P value of less than 0.001, which was considered to be statistically significant. Among different clinicopathologic variables, serum and tissue HER-2/nu were significantly correlated with only tumor grade. Conclusion: A significantly increased release of HER2 ECD levels may accurately predict tumor HER2 status as detected with immunohistochemistry and/or in situ hybridizations studies.Maral MokhtariMohammad Hadi KhosraviShiraz University of Medical Sciencesarticlebreast neoplasmsher 2 proto-oncogene proteinin situ hybridizationNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENMiddle East Journal of Cancer , Vol 12, Iss 4, Pp 483-490 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast neoplasms her 2 proto-oncogene protein in situ hybridization Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	breast neoplasms her 2 proto-oncogene protein in situ hybridization Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Maral Mokhtari Mohammad Hadi Khosravi Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
description	Background: The use of biomarkers has become increasingly important in the diagnosis and treatment of several malignancies, including breast cancer. Among the established biomarkers, receptor tyrosine-protein kinase erbB-2 (HER-2/ neu) has been found to be of a predictive and prognostic role in breast cancer patients. Method: 94 patients with primary breast cancer were enrolled in our prospective study between 2016 and 2017. 5 cc clot blood samples were taken for serum HER- 2/neu testing at the time of diagnosis of breast cancer. The patients’ demographic data, tumor characteristics, including tumor size, tumor grade, presence of lymph node involvement, and stage, hormone receptor, and tissue HER-2/neu status of the subjects were recorded following tumor removal. Results: All of the patients were female with the age range of 27 to 80 years (the mean of age was 49.66. 36 patients (38.3%) had positive tissue HER-2 results and 58 (61.7%) had negative results. In those with high level serum HER-2 ECD, 28(77.7%) had positive tissue HER-2 and 8(22.2%) had negative results. Moreover, in the patients with low level serum HER-2 ECD, 8(13.7%) had positive tissue HER-2 and 50(86.2%) had negative results with the sensitivity of 77.7% and specificity of 86.2%. HER2 ECD levels were highly concordant with tissue HER2 status, with a P value of less than 0.001, which was considered to be statistically significant. Among different clinicopathologic variables, serum and tissue HER-2/nu were significantly correlated with only tumor grade. Conclusion: A significantly increased release of HER2 ECD levels may accurately predict tumor HER2 status as detected with immunohistochemistry and/or in situ hybridizations studies.
format	article
author	Maral Mokhtari Mohammad Hadi Khosravi
author_facet	Maral Mokhtari Mohammad Hadi Khosravi
author_sort	Maral Mokhtari
title	Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
title_short	Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
title_full	Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
title_fullStr	Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
title_full_unstemmed	Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
title_sort	utility of serum her-2/ neu in prediction of tissue her-2 /neu status of primary breast cancer
publisher	Shiraz University of Medical Sciences
publishDate	2021
url	https://doaj.org/article/2506265dea124190a6c339331ad14c1b
work_keys_str_mv	AT maralmokhtari utilityofserumher2neuinpredictionoftissueher2neustatusofprimarybreastcancer AT mohammadhadikhosravi utilityofserumher2neuinpredictionoftissueher2neustatusofprimarybreastcancer
_version_	1718407390975492096

Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer

Ejemplares similares